Grupo Dermatologico Y Estetico Pedro Jaen S.A.
Madrid, 28006, Spain
Location status: Recruiting
NCT Number: NCT07484061
The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1/GIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.
Interested in participating?
Request Info35 year and older
Female
Interventional
Not applicable
Madrid, 28006, Spain
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, amino acids, plant extracts, and other bioactive compounds designed to support hair growth and scalp health in women +45.
Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.
Time frame: From baseline to Day 180.
Ref. Perera E and Sinclair R, 2017
Time frame: From baseline to Day 180.
Comb and Wash Test: this test will quantify the number of fallen hairs (outcome number of shed hairs). It will be carried out after refraining from washing the hair for 48 hours and combing the hair for 24 hours.
Time frame: From baseline to Day 180.
Body weight (Kg). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor
Time frame: From baseline to Day 180.
BMI (Kg/m2). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor
Time frame: From baseline to Day 180.
Fat mass and fat-free mass percentages. Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor
Time frame: From baseline to Day 180.
Serum iron concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum ferritin concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum transferrin concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Transferrin saturation percentage calculated from iron metabolism parameters obtained from blood samples.
Time frame: From baseline to Day 180.
Serum zinc concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum 25-hydroxyvitamin D concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum folate concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum vitamin B12 concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum albumin concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum thyroid-stimulating hormone concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum free thyroxine concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum total testosterone concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum free testosterone concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum dehydroepiandrosterone sulfate concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum sex hormone-binding globulin concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Fasting blood glucose concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Glycated hemoglobin measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Fasting serum insulin concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) calculated from fasting glucose and fasting insulin values.
Time frame: From baseline to Day 180.
Total cholesterol concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
HDL cholesterol concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
LDL cholesterol concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum triglyceride concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
AST concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
ALT concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
GGT concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Blood urea concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Serum creatinine concentration measured in blood samples using standard clinical laboratory methods.
Time frame: From baseline to Day 180.
Subject-reported perception of hair condition assessed using a 12-item questionnaire covering perceived hair density, hair shedding, hair strength, hair volume, appearance, and scalp condition. Each item is rated on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree." Higher scores indicate greater perceived improvement in hair and scalp condition.
Time frame: From baseline to Day 180.
Adherence to the Mediterranean diet assessed using the validated 14-item PREDIMED (Prevención con Dieta Mediterránea) questionnaire. The questionnaire evaluates the frequency of consumption of key food groups and dietary habits characteristic of the Mediterranean diet, including olive oil use, fruit and vegetable intake, legumes, fish, nuts, red meat, sugary beverages, commercial pastries, and wine consumption. Each item is scored 0 or 1, resulting in a total score ranging from 0 to 14, with higher scores indicating greater adherence to the Mediterranean diet.
Olistic Research Labs S.L.
Industry
Evaluation of the Efficacy and Safety of a Drinkable Nutraceutical in Improving Hair Loss in Patients Treated With GLP-1/GIP Receptor Agonists: a Double-blind, 1:1 Randomized, Placebo-controlled Study.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07348120
Alopecia, Hair Diseases
Cairo, Cairo Governorate, Egypt
View Trial DetailsNCT06648850
Alopecia, Androgenetic Alopecia
View Trial DetailsNCT07433933
Alopecia, Androgenetic Alopecia
Alcalá de Henares, Madrid, Spain
View Trial DetailsNCT07412587
Alopecia, Androgenetic Alopecia (AGA)
View Trial Details